INT91913

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 1998
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 16
Total Number 19
Disease Relevance 11.48
Pain Relevance 14.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (GRIN3B)
Anatomy Link Frequency
neuronal 1
brain 1
forebrain 1
microglia 1
GRIN3B (Homo sapiens)
Pain Link Frequency Relevance Heat
nMDA receptor 181 100.00 Very High Very High Very High
antagonist 20 100.00 Very High Very High Very High
nMDA receptor antagonist 19 100.00 Very High Very High Very High
agonist 30 99.84 Very High Very High Very High
methadone 8 99.84 Very High Very High Very High
Glutamate 141 99.62 Very High Very High Very High
Pain 94 99.52 Very High Very High Very High
Opioid 22 99.52 Very High Very High Very High
Dextromethorphan 9 99.52 Very High Very High Very High
cannabis 52 99.48 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 112 99.52 Very High Very High Very High
Opiate Addiction 8 99.52 Very High Very High Very High
Neuropathic Pain 70 99.24 Very High Very High Very High
Disease 31 99.00 Very High Very High Very High
Alcohol Addiction 49 98.84 Very High Very High Very High
Hyperalgesia 6 98.52 Very High Very High Very High
Nervous System Injury 28 98.40 Very High Very High Very High
Fibromyalgia 13 98.12 Very High Very High Very High
Nociception 23 97.40 Very High Very High Very High
Schizophrenia 178 97.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For years, the pharmaceutical industry has been attempting to produce novel compounds that modulate NMDA receptor activity; however, the adverse effects associated with this class of drugs have prevented their widespread clinical use.
Regulation (modulate) of NMDA receptor associated with nmda receptor
1) Confidence 0.61 Published 2000 Journal J Pain Symptom Manage Section Abstract Doc Link 11068158 Disease Relevance 0.42 Pain Relevance 0.83
In the present study, we investigated the effect of the NMDA receptor antagonist memantine (MEM) on the responses of spinothalamic tract (STT) cells in normal and neuropathic monkeys.
Spec (investigated) Regulation (effect) of NMDA receptor associated with spinothalamic tract, nmda receptor antagonist and neuropathic pain
2) Confidence 0.43 Published 1998 Journal Eur J Pain Section Abstract Doc Link 15102383 Disease Relevance 0.61 Pain Relevance 0.61
Because the enhanced WU(SP) of FM patients could be related to abnormal endogenous modulation of NDMA receptors, we tested the effects of the NMDA receptor antagonist dextromethorphan (DEX) on WU(SP) in FM and NC subjects in a double-blind, placebo-controlled, crossover study.
Regulation (effects) of NMDA receptor associated with nmda receptor antagonist, dextromethorphan and fibrositis
3) Confidence 0.43 Published 2005 Journal J Pain Section Abstract Doc Link 15890634 Disease Relevance 0.88 Pain Relevance 0.96
In addition, considerable decrease in the up-regulated state of the NR3B subunit by methadone may represent another benefit of methadone therapy for opioid addicts and may serve as a suitable marker to evaluate the successfulness of therapy.
Regulation (regulated) of NR3B subunit associated with methadone and opioid
4) Confidence 0.39 Published 2010 Journal Eur. J. Pharmacol. Section Abstract Doc Link 20153313 Disease Relevance 0.32 Pain Relevance 1.24
The ontogeny of the NMDA receptor, a multiple tetrameric and heteromeric channel complex with at least six known subunits, is controlled by three gene families and varies in developmental profile with species and regional brain area.
Regulation (controlled) of NMDA receptor in brain associated with nmda receptor
5) Confidence 0.34 Published 2002 Journal Toxicol. Sci. Section Abstract Doc Link 12075105 Disease Relevance 0.42 Pain Relevance 0.62
As a conclusion, our data indicate that the transcriptional level of the NR2D subunit of NMDA receptor is not regulated by chronic opioid addiction.
Neg (not) Regulation (regulated) of NMDA receptor associated with addiction, nmda receptor and opioid
6) Confidence 0.27 Published 2010 Journal Eur. J. Pharmacol. Section Abstract Doc Link 20153313 Disease Relevance 0.33 Pain Relevance 1.25
In contrast, the NMDA receptor antagonist MK-801 (0.1 mg/kg, i.p.) and the AMPA receptor antagonist NS1209 (6 mg/kg, i.p.) did not relieve any of the pain-like behaviours of the SNI animals.
Neg (not) Regulation (relieve) of NMDA receptor associated with pain, nmda receptor antagonist, nervous system injury and antagonist
7) Confidence 0.21 Published 2002 Journal Pain Section Abstract Doc Link 12098627 Disease Relevance 1.49 Pain Relevance 1.84
Therefore, we studied the effects of LA on NMDA receptor function.
Regulation (effects) of NMDA receptor associated with nmda receptor
8) Confidence 0.17 Published 2006 Journal Br J Anaesth Section Abstract Doc Link 16299047 Disease Relevance 0.28 Pain Relevance 0.36
Regulation of NMDA receptor co-agonists through the pharmacological manipulation of DAAO and glycine transporters (GlyT1) have been investigated as putative novel therapeutics to treat schizophrenia.
Spec (investigated) Regulation (Regulation) of NMDA receptor associated with nmda receptor, agonist and schizophrenia
9) Confidence 0.05 Published 2010 Journal The Open Medicinal Chemistry Journal Section Body Doc Link PMC2905773 Disease Relevance 0.45 Pain Relevance 0.56
Importantly, D-serine has been reported to be the predominant NMDA co-agonist in the forebrain and there is accumulating evidence that D-serine regulates cortical and hippocampal NMDA receptor activity [17-19].
Regulation (regulates) of NMDA receptor in forebrain associated with nmda receptor and agonist
10) Confidence 0.05 Published 2010 Journal The Open Medicinal Chemistry Journal Section Body Doc Link PMC2905773 Disease Relevance 0.42 Pain Relevance 0.57
Therapeutics that modulate D-serine and other NMDA receptor co-agonists may better address the multiple symptomatic domains of schizophrenia.
Regulation (modulate) of NMDA receptor associated with nmda receptor, agonist and schizophrenia
11) Confidence 0.04 Published 2010 Journal The Open Medicinal Chemistry Journal Section Body Doc Link PMC2905773 Disease Relevance 0.90 Pain Relevance 0.67
In addition, acute release of NO via nNOS and NMDA receptor activation down-regulates the NMDA receptor, while localized release of 5HT will attenuate the mobilization of Ca2+, NO, and cGMP (Marcoli et al 1997; Maura et al 2000).
Regulation (regulates) of NMDA receptor associated with nmda receptor and 5ht
12) Confidence 0.04 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2413191 Disease Relevance 0.82 Pain Relevance 0.46
Since NO is able to down-regulate its own synthesis both directly on NOS (Griscavage et al 1995) and via down-regulation of the NMDA receptor (McCaslin and Oh 1995), these neuroprotective mechanisms may comprise a possible protective role for NO in the initial stages post stress.
Regulation (regulation) of NMDA receptor associated with stress and nmda receptor
13) Confidence 0.04 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2413191 Disease Relevance 0.74 Pain Relevance 0.23
A likely mechanism of action is the inhibition of neuronal hyperexcitability mediated by antagonism or modulation of pre- and post-synaptic activity of excitatory amino acids, such as glutamate, particularly via modulation of activity at the NMDA receptor (Scott et al 2005)
Regulation (modulation) of NMDA receptor in neuronal associated with glutamate, nmda receptor, hyperexcitability and excitatory amino acid
14) Confidence 0.04 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671951 Disease Relevance 0.20 Pain Relevance 0.96
By functioning to increase GABAergic activity and/or inhibiting glutamatergic activity via modulation of the NMDA receptor, acamprosate may ameliorate alcohol withdrawal symptomotology (Dahchour and De Witte 2000; Boeijinga et al 2004).


Regulation (modulation) of NMDA receptor associated with nmda receptor, gabaergic, withdrawal and alcohol
15) Confidence 0.04 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671951 Disease Relevance 0.26 Pain Relevance 0.96
This finding suggests an increased alteration of GABAA and NMDA receptor activity in cannabis-abusing first-episode patients as compared to schizophrenia patients with no history of substance abuse.
Regulation (alteration) of NMDA receptor associated with cannabis, drug abuse, nmda receptor and schizophrenia
16) Confidence 0.03 Published 2009 Journal Psychopharmacology (Berl) Section Abstract Doc Link PMC2806533 Disease Relevance 1.57 Pain Relevance 0.45
Moreover, by inhibiting its own synthesis (Griscavage et al 1995) and by down-regulating the NMDA receptor by S-nitrosylation at the redox-sensitive site on the receptor (Tanaka et al 1993; McCaslin and Oh 1995), NO will negatively influence its own synthesis and activation.
Regulation (regulating) of NMDA receptor associated with nmda receptor
17) Confidence 0.02 Published 2005 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2413191 Disease Relevance 0.73 Pain Relevance 0.14
In the ACC, the induction of LTP by different protocols is mostly NMDA receptor dependent.
Regulation (dependent) of NMDA receptor associated with nmda receptor, long-term potentiation and anterior cingulate cortex
18) Confidence 0.01 Published 2007 Journal Mol Pain Section Body Doc Link PMC1904186 Disease Relevance 0.36 Pain Relevance 1.14
Although they have not identified the molecule(s) yet, they suggested that both heat- and protease-labile molecules released from microglia regulate NMDA receptor-mediated excitatory synaptic transmission in the CNS.
Regulation (regulate) of NMDA receptor in microglia associated with nmda receptor
19) Confidence 0.01 Published 2005 Journal Purinergic Signal Section Body Doc Link PMC2096535 Disease Relevance 0.28 Pain Relevance 0.60

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox